Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Biotech
Context ends bispecific trial to extend runway deeper into 2027
Context stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on two priority programs.
Nick Paul Taylor
Aug 6, 2026 5:55am
Vertex’s latest autoimmune TCE play involves $28M to AbCellera
Jul 29, 2026 8:20am
Roche drops lupus TCE, retains autoimmune cell therapy interest
Jul 23, 2026 4:51am
Deerfield’s Boulevard Bio pens $1.6B deal for trispecific TCE
Jun 30, 2026 8:00am
Cullinan's new data makes clearest case yet for autoimmune TCEs
Jun 6, 2026 5:15am
Pfizer’s $2.3B bet ends in failure as CD47 blocker scrapped
May 5, 2026 9:15am
